nodes	percent_of_prediction	percent_of_DWPC	metapath
Losartan—CYP3A4—bone cancer	0.382	1	CbGaD
Losartan—UGT2B7—Epirubicin—bone cancer	0.147	0.369	CbGbCtD
Losartan—SLCO1B3—Methotrexate—bone cancer	0.0775	0.195	CbGbCtD
Losartan—SLCO1B1—Methotrexate—bone cancer	0.0451	0.114	CbGbCtD
Losartan—SLC22A6—Methotrexate—bone cancer	0.029	0.073	CbGbCtD
Losartan—ALB—Methotrexate—bone cancer	0.0247	0.0622	CbGbCtD
Losartan—CYP2C9—Cisplatin—bone cancer	0.0205	0.0516	CbGbCtD
Losartan—ABCB1—Cisplatin—bone cancer	0.0199	0.0501	CbGbCtD
Losartan—ABCB1—Doxorubicin—bone cancer	0.0133	0.0336	CbGbCtD
Losartan—ABCB1—Methotrexate—bone cancer	0.0129	0.0325	CbGbCtD
Losartan—CYP3A4—Doxorubicin—bone cancer	0.008	0.0201	CbGbCtD
Losartan—Irbesartan—JUN—bone cancer	0.00411	0.702	CrCbGaD
Losartan—Tasosartan—CYP3A4—bone cancer	0.00105	0.18	CrCbGaD
Losartan—Irbesartan—CYP3A4—bone cancer	0.000692	0.118	CrCbGaD
Losartan—Decreased appetite—Cisplatin—bone cancer	0.000271	0.00239	CcSEcCtD
Losartan—Bronchitis—Epirubicin—bone cancer	0.000271	0.00238	CcSEcCtD
Losartan—Pneumonia—Methotrexate—bone cancer	0.00027	0.00238	CcSEcCtD
Losartan—Gastritis—Doxorubicin—bone cancer	0.000267	0.00235	CcSEcCtD
Losartan—Pain—Cisplatin—bone cancer	0.000267	0.00235	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000266	0.00234	CcSEcCtD
Losartan—Muscular weakness—Doxorubicin—bone cancer	0.000266	0.00234	CcSEcCtD
Losartan—Renal failure—Methotrexate—bone cancer	0.000264	0.00232	CcSEcCtD
Losartan—Upper respiratory tract infection—Epirubicin—bone cancer	0.000262	0.0023	CcSEcCtD
Losartan—Conjunctivitis—Methotrexate—bone cancer	0.000261	0.0023	CcSEcCtD
Losartan—Influenza—Doxorubicin—bone cancer	0.000261	0.00229	CcSEcCtD
Losartan—Pollakiuria—Epirubicin—bone cancer	0.00026	0.00229	CcSEcCtD
Losartan—Eosinophilia—Doxorubicin—bone cancer	0.000258	0.00227	CcSEcCtD
Losartan—Sweating—Methotrexate—bone cancer	0.000257	0.00227	CcSEcCtD
Losartan—Photosensitivity reaction—Epirubicin—bone cancer	0.000257	0.00226	CcSEcCtD
Losartan—Feeling abnormal—Cisplatin—bone cancer	0.000257	0.00226	CcSEcCtD
Losartan—Weight increased—Epirubicin—bone cancer	0.000257	0.00226	CcSEcCtD
Losartan—Pancreatitis—Doxorubicin—bone cancer	0.000256	0.00225	CcSEcCtD
Losartan—Hyperglycaemia—Epirubicin—bone cancer	0.000254	0.00224	CcSEcCtD
Losartan—Angina pectoris—Doxorubicin—bone cancer	0.000254	0.00224	CcSEcCtD
Losartan—Epistaxis—Methotrexate—bone cancer	0.000253	0.00223	CcSEcCtD
Losartan—Pneumonia—Epirubicin—bone cancer	0.000253	0.00222	CcSEcCtD
Losartan—Bronchitis—Doxorubicin—bone cancer	0.000251	0.00221	CcSEcCtD
Losartan—Agranulocytosis—Methotrexate—bone cancer	0.000251	0.0022	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000249	0.00219	CcSEcCtD
Losartan—Renal failure—Epirubicin—bone cancer	0.000247	0.00217	CcSEcCtD
Losartan—Body temperature increased—Cisplatin—bone cancer	0.000247	0.00217	CcSEcCtD
Losartan—Neuropathy peripheral—Epirubicin—bone cancer	0.000246	0.00217	CcSEcCtD
Losartan—Jaundice—Epirubicin—bone cancer	0.000245	0.00216	CcSEcCtD
Losartan—Urinary tract infection—Epirubicin—bone cancer	0.000244	0.00215	CcSEcCtD
Losartan—Conjunctivitis—Epirubicin—bone cancer	0.000244	0.00215	CcSEcCtD
Losartan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000242	0.00213	CcSEcCtD
Losartan—Hepatitis—Methotrexate—bone cancer	0.000241	0.00212	CcSEcCtD
Losartan—Sweating—Epirubicin—bone cancer	0.000241	0.00212	CcSEcCtD
Losartan—Pollakiuria—Doxorubicin—bone cancer	0.000241	0.00212	CcSEcCtD
Losartan—Pharyngitis—Methotrexate—bone cancer	0.000239	0.00211	CcSEcCtD
Losartan—Photosensitivity reaction—Doxorubicin—bone cancer	0.000238	0.00209	CcSEcCtD
Losartan—Weight increased—Doxorubicin—bone cancer	0.000237	0.00209	CcSEcCtD
Losartan—Epistaxis—Epirubicin—bone cancer	0.000237	0.00209	CcSEcCtD
Losartan—Sinusitis—Epirubicin—bone cancer	0.000236	0.00207	CcSEcCtD
Losartan—Hyperglycaemia—Doxorubicin—bone cancer	0.000235	0.00207	CcSEcCtD
Losartan—Agranulocytosis—Epirubicin—bone cancer	0.000235	0.00206	CcSEcCtD
Losartan—Pneumonia—Doxorubicin—bone cancer	0.000234	0.00206	CcSEcCtD
Losartan—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000231	0.00203	CcSEcCtD
Losartan—Hypersensitivity—Cisplatin—bone cancer	0.00023	0.00202	CcSEcCtD
Losartan—Renal failure—Doxorubicin—bone cancer	0.000229	0.00201	CcSEcCtD
Losartan—Erythema multiforme—Methotrexate—bone cancer	0.000228	0.00201	CcSEcCtD
Losartan—Neuropathy peripheral—Doxorubicin—bone cancer	0.000228	0.00201	CcSEcCtD
Losartan—Jaundice—Doxorubicin—bone cancer	0.000227	0.00199	CcSEcCtD
Losartan—Rhinitis—Epirubicin—bone cancer	0.000226	0.00199	CcSEcCtD
Losartan—Urinary tract infection—Doxorubicin—bone cancer	0.000226	0.00199	CcSEcCtD
Losartan—Conjunctivitis—Doxorubicin—bone cancer	0.000226	0.00199	CcSEcCtD
Losartan—Hepatitis—Epirubicin—bone cancer	0.000226	0.00198	CcSEcCtD
Losartan—Tinnitus—Methotrexate—bone cancer	0.000225	0.00198	CcSEcCtD
Losartan—Hypoaesthesia—Epirubicin—bone cancer	0.000225	0.00197	CcSEcCtD
Losartan—Asthenia—Cisplatin—bone cancer	0.000224	0.00197	CcSEcCtD
Losartan—Pharyngitis—Epirubicin—bone cancer	0.000224	0.00197	CcSEcCtD
Losartan—Sweating—Doxorubicin—bone cancer	0.000223	0.00196	CcSEcCtD
Losartan—Epistaxis—Doxorubicin—bone cancer	0.000219	0.00193	CcSEcCtD
Losartan—Angiopathy—Methotrexate—bone cancer	0.000219	0.00192	CcSEcCtD
Losartan—Sinusitis—Doxorubicin—bone cancer	0.000218	0.00192	CcSEcCtD
Losartan—UGT2B17—Metabolism—ENO2—bone cancer	0.000217	0.00215	CbGpPWpGaD
Losartan—Agranulocytosis—Doxorubicin—bone cancer	0.000217	0.00191	CcSEcCtD
Losartan—AGTR1—GPCR ligand binding—GRM1—bone cancer	0.000214	0.00211	CbGpPWpGaD
Losartan—Diarrhoea—Cisplatin—bone cancer	0.000214	0.00188	CcSEcCtD
Losartan—Erythema multiforme—Epirubicin—bone cancer	0.000213	0.00188	CcSEcCtD
Losartan—Alopecia—Methotrexate—bone cancer	0.000213	0.00187	CcSEcCtD
Losartan—Tinnitus—Epirubicin—bone cancer	0.00021	0.00185	CcSEcCtD
Losartan—UGT1A3—Biological oxidations—GSTP1—bone cancer	0.00021	0.00207	CbGpPWpGaD
Losartan—Erythema—Methotrexate—bone cancer	0.00021	0.00185	CcSEcCtD
Losartan—Flushing—Epirubicin—bone cancer	0.000209	0.00184	CcSEcCtD
Losartan—Rhinitis—Doxorubicin—bone cancer	0.000209	0.00184	CcSEcCtD
Losartan—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.000209	0.00206	CbGpPWpGaD
Losartan—Hepatitis—Doxorubicin—bone cancer	0.000209	0.00184	CcSEcCtD
Losartan—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000208	0.00205	CbGpPWpGaD
Losartan—Hypoaesthesia—Doxorubicin—bone cancer	0.000208	0.00183	CcSEcCtD
Losartan—UGT1A3—Metapathway biotransformation—GSTP1—bone cancer	0.000207	0.00205	CbGpPWpGaD
Losartan—Pharyngitis—Doxorubicin—bone cancer	0.000207	0.00182	CcSEcCtD
Losartan—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000206	0.00203	CbGpPWpGaD
Losartan—Dysgeusia—Methotrexate—bone cancer	0.000206	0.00181	CcSEcCtD
Losartan—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000205	0.00202	CbGpPWpGaD
Losartan—Angiopathy—Epirubicin—bone cancer	0.000205	0.0018	CcSEcCtD
Losartan—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000204	0.00201	CbGpPWpGaD
Losartan—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000204	0.00201	CbGpPWpGaD
Losartan—Back pain—Methotrexate—bone cancer	0.000203	0.00179	CcSEcCtD
Losartan—UGT2B17—Metabolism—DHFR—bone cancer	0.000202	0.00199	CbGpPWpGaD
Losartan—Arrhythmia—Epirubicin—bone cancer	0.000202	0.00177	CcSEcCtD
Losartan—Alopecia—Epirubicin—bone cancer	0.000199	0.00175	CcSEcCtD
Losartan—Vomiting—Cisplatin—bone cancer	0.000198	0.00175	CcSEcCtD
Losartan—ALB—Platelet degranulation—SPARC—bone cancer	0.000198	0.00195	CbGpPWpGaD
Losartan—Vision blurred—Methotrexate—bone cancer	0.000198	0.00174	CcSEcCtD
Losartan—Erythema multiforme—Doxorubicin—bone cancer	0.000197	0.00174	CcSEcCtD
Losartan—Rash—Cisplatin—bone cancer	0.000197	0.00173	CcSEcCtD
Losartan—Dermatitis—Cisplatin—bone cancer	0.000197	0.00173	CcSEcCtD
Losartan—Erythema—Epirubicin—bone cancer	0.000196	0.00173	CcSEcCtD
Losartan—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000196	0.00194	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000195	0.00192	CbGpPWpGaD
Losartan—Ill-defined disorder—Methotrexate—bone cancer	0.000195	0.00171	CcSEcCtD
Losartan—Tinnitus—Doxorubicin—bone cancer	0.000195	0.00171	CcSEcCtD
Losartan—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000194	0.00192	CbGpPWpGaD
Losartan—Anaemia—Methotrexate—bone cancer	0.000194	0.00171	CcSEcCtD
Losartan—Flushing—Doxorubicin—bone cancer	0.000194	0.0017	CcSEcCtD
Losartan—Flatulence—Epirubicin—bone cancer	0.000194	0.0017	CcSEcCtD
Losartan—Tension—Epirubicin—bone cancer	0.000193	0.0017	CcSEcCtD
Losartan—Dysgeusia—Epirubicin—bone cancer	0.000192	0.00169	CcSEcCtD
Losartan—Nervousness—Epirubicin—bone cancer	0.000191	0.00168	CcSEcCtD
Losartan—Back pain—Epirubicin—bone cancer	0.00019	0.00167	CcSEcCtD
Losartan—Angiopathy—Doxorubicin—bone cancer	0.000189	0.00167	CcSEcCtD
Losartan—Malaise—Methotrexate—bone cancer	0.000189	0.00167	CcSEcCtD
Losartan—Muscle spasms—Epirubicin—bone cancer	0.000189	0.00166	CcSEcCtD
Losartan—UGT2B17—Metabolism—GNA11—bone cancer	0.000189	0.00186	CbGpPWpGaD
Losartan—Vertigo—Methotrexate—bone cancer	0.000189	0.00166	CcSEcCtD
Losartan—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000189	0.00186	CbGpPWpGaD
Losartan—Leukopenia—Methotrexate—bone cancer	0.000188	0.00165	CcSEcCtD
Losartan—Arrhythmia—Doxorubicin—bone cancer	0.000187	0.00164	CcSEcCtD
Losartan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000185	0.00183	CbGpPWpGaD
Losartan—Nausea—Cisplatin—bone cancer	0.000185	0.00163	CcSEcCtD
Losartan—Vision blurred—Epirubicin—bone cancer	0.000185	0.00163	CcSEcCtD
Losartan—Alopecia—Doxorubicin—bone cancer	0.000184	0.00162	CcSEcCtD
Losartan—Cough—Methotrexate—bone cancer	0.000183	0.00161	CcSEcCtD
Losartan—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000183	0.0018	CbGpPWpGaD
Losartan—Ill-defined disorder—Epirubicin—bone cancer	0.000182	0.0016	CcSEcCtD
Losartan—Erythema—Doxorubicin—bone cancer	0.000182	0.0016	CcSEcCtD
Losartan—Anaemia—Epirubicin—bone cancer	0.000182	0.0016	CcSEcCtD
Losartan—Agitation—Epirubicin—bone cancer	0.000181	0.00159	CcSEcCtD
Losartan—Flatulence—Doxorubicin—bone cancer	0.000179	0.00158	CcSEcCtD
Losartan—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000179	0.00176	CbGpPWpGaD
Losartan—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000179	0.00176	CbGpPWpGaD
Losartan—Arthralgia—Methotrexate—bone cancer	0.000179	0.00157	CcSEcCtD
Losartan—Chest pain—Methotrexate—bone cancer	0.000179	0.00157	CcSEcCtD
Losartan—Myalgia—Methotrexate—bone cancer	0.000179	0.00157	CcSEcCtD
Losartan—Tension—Doxorubicin—bone cancer	0.000178	0.00157	CcSEcCtD
Losartan—Dysgeusia—Doxorubicin—bone cancer	0.000178	0.00157	CcSEcCtD
Losartan—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000178	0.00175	CbGpPWpGaD
Losartan—Malaise—Epirubicin—bone cancer	0.000177	0.00156	CcSEcCtD
Losartan—Discomfort—Methotrexate—bone cancer	0.000177	0.00155	CcSEcCtD
Losartan—Nervousness—Doxorubicin—bone cancer	0.000177	0.00155	CcSEcCtD
Losartan—Vertigo—Epirubicin—bone cancer	0.000176	0.00155	CcSEcCtD
Losartan—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000176	0.00174	CbGpPWpGaD
Losartan—Syncope—Epirubicin—bone cancer	0.000176	0.00155	CcSEcCtD
Losartan—Leukopenia—Epirubicin—bone cancer	0.000176	0.00155	CcSEcCtD
Losartan—Back pain—Doxorubicin—bone cancer	0.000176	0.00155	CcSEcCtD
Losartan—Muscle spasms—Doxorubicin—bone cancer	0.000175	0.00154	CcSEcCtD
Losartan—Palpitations—Epirubicin—bone cancer	0.000174	0.00153	CcSEcCtD
Losartan—Confusional state—Methotrexate—bone cancer	0.000173	0.00152	CcSEcCtD
Losartan—Loss of consciousness—Epirubicin—bone cancer	0.000173	0.00152	CcSEcCtD
Losartan—Cough—Epirubicin—bone cancer	0.000171	0.00151	CcSEcCtD
Losartan—Anaphylactic shock—Methotrexate—bone cancer	0.000171	0.00151	CcSEcCtD
Losartan—Vision blurred—Doxorubicin—bone cancer	0.000171	0.00151	CcSEcCtD
Losartan—UGT2B17—Metabolism—CYP3A4—bone cancer	0.000171	0.00169	CbGpPWpGaD
Losartan—Infection—Methotrexate—bone cancer	0.00017	0.0015	CcSEcCtD
Losartan—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.00017	0.00168	CbGpPWpGaD
Losartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000169	0.00167	CbGpPWpGaD
Losartan—Ill-defined disorder—Doxorubicin—bone cancer	0.000169	0.00148	CcSEcCtD
Losartan—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000168	0.00166	CbGpPWpGaD
Losartan—Nervous system disorder—Methotrexate—bone cancer	0.000168	0.00148	CcSEcCtD
Losartan—Anaemia—Doxorubicin—bone cancer	0.000168	0.00148	CcSEcCtD
Losartan—Thrombocytopenia—Methotrexate—bone cancer	0.000168	0.00148	CcSEcCtD
Losartan—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000168	0.00165	CbGpPWpGaD
Losartan—Arthralgia—Epirubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Losartan—Chest pain—Epirubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Losartan—Myalgia—Epirubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Losartan—Agitation—Doxorubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Losartan—ACE—Metabolism of proteins—EIF2S1—bone cancer	0.000167	0.00165	CbGpPWpGaD
Losartan—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000167	0.00165	CbGpPWpGaD
Losartan—Anxiety—Epirubicin—bone cancer	0.000167	0.00147	CcSEcCtD
Losartan—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.000166	0.00163	CbGpPWpGaD
Losartan—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.000166	0.00163	CbGpPWpGaD
Losartan—Hyperhidrosis—Methotrexate—bone cancer	0.000166	0.00146	CcSEcCtD
Losartan—Discomfort—Epirubicin—bone cancer	0.000165	0.00145	CcSEcCtD
Losartan—Malaise—Doxorubicin—bone cancer	0.000164	0.00144	CcSEcCtD
Losartan—Dry mouth—Epirubicin—bone cancer	0.000164	0.00144	CcSEcCtD
Losartan—Vertigo—Doxorubicin—bone cancer	0.000163	0.00144	CcSEcCtD
Losartan—Anorexia—Methotrexate—bone cancer	0.000163	0.00144	CcSEcCtD
Losartan—Syncope—Doxorubicin—bone cancer	0.000163	0.00143	CcSEcCtD
Losartan—Leukopenia—Doxorubicin—bone cancer	0.000163	0.00143	CcSEcCtD
Losartan—Confusional state—Epirubicin—bone cancer	0.000162	0.00142	CcSEcCtD
Losartan—Palpitations—Doxorubicin—bone cancer	0.000161	0.00141	CcSEcCtD
Losartan—Oedema—Epirubicin—bone cancer	0.00016	0.00141	CcSEcCtD
Losartan—Anaphylactic shock—Epirubicin—bone cancer	0.00016	0.00141	CcSEcCtD
Losartan—Hypotension—Methotrexate—bone cancer	0.00016	0.00141	CcSEcCtD
Losartan—Loss of consciousness—Doxorubicin—bone cancer	0.00016	0.00141	CcSEcCtD
Losartan—Infection—Epirubicin—bone cancer	0.000159	0.0014	CcSEcCtD
Losartan—Cough—Doxorubicin—bone cancer	0.000159	0.0014	CcSEcCtD
Losartan—Shock—Epirubicin—bone cancer	0.000158	0.00139	CcSEcCtD
Losartan—Nervous system disorder—Epirubicin—bone cancer	0.000157	0.00138	CcSEcCtD
Losartan—Thrombocytopenia—Epirubicin—bone cancer	0.000157	0.00138	CcSEcCtD
Losartan—Tachycardia—Epirubicin—bone cancer	0.000156	0.00138	CcSEcCtD
Losartan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000156	0.00137	CcSEcCtD
Losartan—Hyperhidrosis—Epirubicin—bone cancer	0.000155	0.00136	CcSEcCtD
Losartan—Insomnia—Methotrexate—bone cancer	0.000155	0.00136	CcSEcCtD
Losartan—Arthralgia—Doxorubicin—bone cancer	0.000155	0.00136	CcSEcCtD
Losartan—Myalgia—Doxorubicin—bone cancer	0.000155	0.00136	CcSEcCtD
Losartan—Chest pain—Doxorubicin—bone cancer	0.000155	0.00136	CcSEcCtD
Losartan—Anxiety—Doxorubicin—bone cancer	0.000154	0.00136	CcSEcCtD
Losartan—Paraesthesia—Methotrexate—bone cancer	0.000154	0.00135	CcSEcCtD
Losartan—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000153	0.00151	CbGpPWpGaD
Losartan—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000153	0.00151	CbGpPWpGaD
Losartan—Discomfort—Doxorubicin—bone cancer	0.000153	0.00134	CcSEcCtD
Losartan—Anorexia—Epirubicin—bone cancer	0.000153	0.00134	CcSEcCtD
Losartan—Dyspnoea—Methotrexate—bone cancer	0.000153	0.00134	CcSEcCtD
Losartan—Somnolence—Methotrexate—bone cancer	0.000152	0.00134	CcSEcCtD
Losartan—Dry mouth—Doxorubicin—bone cancer	0.000151	0.00133	CcSEcCtD
Losartan—AGTR1—GPCR ligand binding—SMO—bone cancer	0.000151	0.00149	CbGpPWpGaD
Losartan—Dyspepsia—Methotrexate—bone cancer	0.000151	0.00133	CcSEcCtD
Losartan—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00015	0.00148	CbGpPWpGaD
Losartan—Hypotension—Epirubicin—bone cancer	0.00015	0.00132	CcSEcCtD
Losartan—Confusional state—Doxorubicin—bone cancer	0.00015	0.00132	CcSEcCtD
Losartan—Decreased appetite—Methotrexate—bone cancer	0.000149	0.00131	CcSEcCtD
Losartan—Anaphylactic shock—Doxorubicin—bone cancer	0.000148	0.0013	CcSEcCtD
Losartan—Oedema—Doxorubicin—bone cancer	0.000148	0.0013	CcSEcCtD
Losartan—Fatigue—Methotrexate—bone cancer	0.000148	0.0013	CcSEcCtD
Losartan—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000147	0.00145	CbGpPWpGaD
Losartan—Infection—Doxorubicin—bone cancer	0.000147	0.0013	CcSEcCtD
Losartan—Pain—Methotrexate—bone cancer	0.000146	0.00129	CcSEcCtD
Losartan—UGT2B17—Metabolism—GSTP1—bone cancer	0.000146	0.00144	CbGpPWpGaD
Losartan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000146	0.00128	CcSEcCtD
Losartan—Shock—Doxorubicin—bone cancer	0.000146	0.00128	CcSEcCtD
Losartan—Nervous system disorder—Doxorubicin—bone cancer	0.000145	0.00128	CcSEcCtD
Losartan—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000145	0.00143	CbGpPWpGaD
Losartan—Thrombocytopenia—Doxorubicin—bone cancer	0.000145	0.00128	CcSEcCtD
Losartan—Insomnia—Epirubicin—bone cancer	0.000145	0.00128	CcSEcCtD
Losartan—Tachycardia—Doxorubicin—bone cancer	0.000145	0.00127	CcSEcCtD
Losartan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000144	0.00142	CbGpPWpGaD
Losartan—Paraesthesia—Epirubicin—bone cancer	0.000144	0.00127	CcSEcCtD
Losartan—Hyperhidrosis—Doxorubicin—bone cancer	0.000143	0.00126	CcSEcCtD
Losartan—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000143	0.00141	CbGpPWpGaD
Losartan—Dyspnoea—Epirubicin—bone cancer	0.000143	0.00126	CcSEcCtD
Losartan—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000143	0.00141	CbGpPWpGaD
Losartan—Somnolence—Epirubicin—bone cancer	0.000143	0.00125	CcSEcCtD
Losartan—Anorexia—Doxorubicin—bone cancer	0.000141	0.00124	CcSEcCtD
Losartan—Feeling abnormal—Methotrexate—bone cancer	0.000141	0.00124	CcSEcCtD
Losartan—Dyspepsia—Epirubicin—bone cancer	0.000141	0.00124	CcSEcCtD
Losartan—Gastrointestinal pain—Methotrexate—bone cancer	0.00014	0.00123	CcSEcCtD
Losartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	0.00014	0.00138	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	0.00014	0.00138	CbGpPWpGaD
Losartan—Decreased appetite—Epirubicin—bone cancer	0.000139	0.00123	CcSEcCtD
Losartan—SLCO1B3—Metabolism—NDUFA12—bone cancer	0.000139	0.00137	CbGpPWpGaD
Losartan—Hypotension—Doxorubicin—bone cancer	0.000139	0.00122	CcSEcCtD
Losartan—Fatigue—Epirubicin—bone cancer	0.000138	0.00122	CcSEcCtD
Losartan—Constipation—Epirubicin—bone cancer	0.000137	0.00121	CcSEcCtD
Losartan—Pain—Epirubicin—bone cancer	0.000137	0.00121	CcSEcCtD
Losartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000137	0.00135	CbGpPWpGaD
Losartan—Urticaria—Methotrexate—bone cancer	0.000136	0.0012	CcSEcCtD
Losartan—Abdominal pain—Methotrexate—bone cancer	0.000135	0.00119	CcSEcCtD
Losartan—Body temperature increased—Methotrexate—bone cancer	0.000135	0.00119	CcSEcCtD
Losartan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000135	0.00119	CcSEcCtD
Losartan—Insomnia—Doxorubicin—bone cancer	0.000134	0.00118	CcSEcCtD
Losartan—Paraesthesia—Doxorubicin—bone cancer	0.000133	0.00117	CcSEcCtD
Losartan—Dyspnoea—Doxorubicin—bone cancer	0.000132	0.00116	CcSEcCtD
Losartan—Feeling abnormal—Epirubicin—bone cancer	0.000132	0.00116	CcSEcCtD
Losartan—Somnolence—Doxorubicin—bone cancer	0.000132	0.00116	CcSEcCtD
Losartan—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000131	0.00129	CbGpPWpGaD
Losartan—Gastrointestinal pain—Epirubicin—bone cancer	0.000131	0.00115	CcSEcCtD
Losartan—Dyspepsia—Doxorubicin—bone cancer	0.000131	0.00115	CcSEcCtD
Losartan—Decreased appetite—Doxorubicin—bone cancer	0.000129	0.00113	CcSEcCtD
Losartan—Fatigue—Doxorubicin—bone cancer	0.000128	0.00112	CcSEcCtD
Losartan—Urticaria—Epirubicin—bone cancer	0.000127	0.00112	CcSEcCtD
Losartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	0.000127	0.00125	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	0.000127	0.00125	CbGpPWpGaD
Losartan—Constipation—Doxorubicin—bone cancer	0.000127	0.00112	CcSEcCtD
Losartan—Pain—Doxorubicin—bone cancer	0.000127	0.00112	CcSEcCtD
Losartan—Body temperature increased—Epirubicin—bone cancer	0.000127	0.00111	CcSEcCtD
Losartan—Abdominal pain—Epirubicin—bone cancer	0.000127	0.00111	CcSEcCtD
Losartan—Hypersensitivity—Methotrexate—bone cancer	0.000126	0.00111	CcSEcCtD
Losartan—UGT2B7—Metabolism—NDUFA12—bone cancer	0.000125	0.00124	CbGpPWpGaD
Losartan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000124	0.00122	CbGpPWpGaD
Losartan—Asthenia—Methotrexate—bone cancer	0.000123	0.00108	CcSEcCtD
Losartan—Feeling abnormal—Doxorubicin—bone cancer	0.000122	0.00108	CcSEcCtD
Losartan—UGT1A3—Metabolism—NT5C3A—bone cancer	0.000122	0.0012	CbGpPWpGaD
Losartan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000121	0.00107	CcSEcCtD
Losartan—Pruritus—Methotrexate—bone cancer	0.000121	0.00107	CcSEcCtD
Losartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	0.000121	0.0012	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000119	0.00118	CbGpPWpGaD
Losartan—Hypersensitivity—Epirubicin—bone cancer	0.000118	0.00104	CcSEcCtD
Losartan—Urticaria—Doxorubicin—bone cancer	0.000118	0.00104	CcSEcCtD
Losartan—Abdominal pain—Doxorubicin—bone cancer	0.000117	0.00103	CcSEcCtD
Losartan—Body temperature increased—Doxorubicin—bone cancer	0.000117	0.00103	CcSEcCtD
Losartan—Diarrhoea—Methotrexate—bone cancer	0.000117	0.00103	CcSEcCtD
Losartan—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000117	0.00116	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—NT5C3A—bone cancer	0.000115	0.00114	CbGpPWpGaD
Losartan—Asthenia—Epirubicin—bone cancer	0.000115	0.00101	CcSEcCtD
Losartan—Pruritus—Epirubicin—bone cancer	0.000113	0.000998	CcSEcCtD
Losartan—Dizziness—Methotrexate—bone cancer	0.000113	0.000996	CcSEcCtD
Losartan—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000113	0.00112	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	0.00011	0.00109	CbGpPWpGaD
Losartan—Diarrhoea—Epirubicin—bone cancer	0.00011	0.000965	CcSEcCtD
Losartan—Hypersensitivity—Doxorubicin—bone cancer	0.000109	0.000961	CcSEcCtD
Losartan—Vomiting—Methotrexate—bone cancer	0.000109	0.000958	CcSEcCtD
Losartan—Rash—Methotrexate—bone cancer	0.000108	0.00095	CcSEcCtD
Losartan—Dermatitis—Methotrexate—bone cancer	0.000108	0.000949	CcSEcCtD
Losartan—Headache—Methotrexate—bone cancer	0.000107	0.000944	CcSEcCtD
Losartan—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000106	0.00105	CbGpPWpGaD
Losartan—Asthenia—Doxorubicin—bone cancer	0.000106	0.000936	CcSEcCtD
Losartan—Dizziness—Epirubicin—bone cancer	0.000106	0.000933	CcSEcCtD
Losartan—Pruritus—Doxorubicin—bone cancer	0.000105	0.000923	CcSEcCtD
Losartan—UGT2B7—Metabolism—NT5C3A—bone cancer	0.000104	0.00102	CbGpPWpGaD
Losartan—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000103	0.00102	CbGpPWpGaD
Losartan—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000103	0.00102	CbGpPWpGaD
Losartan—Vomiting—Epirubicin—bone cancer	0.000102	0.000897	CcSEcCtD
Losartan—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000102	0.001	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—NDUFA12—bone cancer	0.000102	0.001	CbGpPWpGaD
Losartan—Nausea—Methotrexate—bone cancer	0.000102	0.000895	CcSEcCtD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000102	0.001	CbGpPWpGaD
Losartan—Diarrhoea—Doxorubicin—bone cancer	0.000101	0.000893	CcSEcCtD
Losartan—Rash—Epirubicin—bone cancer	0.000101	0.000889	CcSEcCtD
Losartan—Dermatitis—Epirubicin—bone cancer	0.000101	0.000888	CcSEcCtD
Losartan—Headache—Epirubicin—bone cancer	0.0001	0.000883	CcSEcCtD
Losartan—Dizziness—Doxorubicin—bone cancer	9.81e-05	0.000863	CcSEcCtD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	9.63e-05	0.00095	CbGpPWpGaD
Losartan—Nausea—Epirubicin—bone cancer	9.52e-05	0.000838	CcSEcCtD
Losartan—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	9.51e-05	0.000938	CbGpPWpGaD
Losartan—Vomiting—Doxorubicin—bone cancer	9.43e-05	0.00083	CcSEcCtD
Losartan—Rash—Doxorubicin—bone cancer	9.35e-05	0.000823	CcSEcCtD
Losartan—Dermatitis—Doxorubicin—bone cancer	9.34e-05	0.000822	CcSEcCtD
Losartan—SLCO1B1—Metabolism—NDUFA12—bone cancer	9.33e-05	0.00092	CbGpPWpGaD
Losartan—Headache—Doxorubicin—bone cancer	9.29e-05	0.000817	CcSEcCtD
Losartan—CYP1A2—Phase II conjugation—GSTP1—bone cancer	9.1e-05	0.000897	CbGpPWpGaD
Losartan—CYP2C8—Biological oxidations—CYP3A4—bone cancer	8.95e-05	0.000882	CbGpPWpGaD
Losartan—CYP3A5—Biological oxidations—GSTP1—bone cancer	8.83e-05	0.000871	CbGpPWpGaD
Losartan—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	8.82e-05	0.00087	CbGpPWpGaD
Losartan—Nausea—Doxorubicin—bone cancer	8.81e-05	0.000775	CcSEcCtD
Losartan—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	8.78e-05	0.000866	CbGpPWpGaD
Losartan—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	8.71e-05	0.000859	CbGpPWpGaD
Losartan—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.67e-05	0.000855	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.64e-05	0.000852	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—NT5C3A—bone cancer	8.44e-05	0.000832	CbGpPWpGaD
Losartan—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	8.21e-05	0.00081	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	8.03e-05	0.000792	CbGpPWpGaD
Losartan—CYP2C19—Biological oxidations—CYP3A4—bone cancer	7.98e-05	0.000788	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	7.92e-05	0.000781	CbGpPWpGaD
Losartan—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	7.87e-05	0.000777	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.87e-05	0.000776	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	7.81e-05	0.00077	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—SMO—bone cancer	7.75e-05	0.000765	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—NT5C3A—bone cancer	7.73e-05	0.000763	CbGpPWpGaD
Losartan—CYP2C8—Biological oxidations—GSTP1—bone cancer	7.65e-05	0.000755	CbGpPWpGaD
Losartan—UGT2B17—Metabolism—PTGS2—bone cancer	7.57e-05	0.000747	CbGpPWpGaD
Losartan—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.55e-05	0.000744	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—GRM4—bone cancer	7.5e-05	0.000739	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—RGS1—bone cancer	7.5e-05	0.000739	CbGpPWpGaD
Losartan—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	7.41e-05	0.000731	CbGpPWpGaD
Losartan—CYP2C9—Biological oxidations—CYP3A4—bone cancer	7.28e-05	0.000718	CbGpPWpGaD
Losartan—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	7.28e-05	0.000718	CbGpPWpGaD
Losartan—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	7.18e-05	0.000708	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.17e-05	0.000707	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.14e-05	0.000704	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	7.09e-05	0.000699	CbGpPWpGaD
Losartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	7.08e-05	0.000698	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.07e-05	0.000697	CbGpPWpGaD
Losartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	6.98e-05	0.000688	CbGpPWpGaD
Losartan—CYP2C19—Biological oxidations—GSTP1—bone cancer	6.83e-05	0.000674	CbGpPWpGaD
Losartan—ACE—Metabolism of proteins—MMP2—bone cancer	6.83e-05	0.000674	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.82e-05	0.000673	CbGpPWpGaD
Losartan—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	6.74e-05	0.000664	CbGpPWpGaD
Losartan—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.73e-05	0.000664	CbGpPWpGaD
Losartan—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.7e-05	0.000661	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—GRM1—bone cancer	6.5e-05	0.000641	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—IL3—bone cancer	6.43e-05	0.000634	CbGpPWpGaD
Losartan—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.34e-05	0.000625	CbGpPWpGaD
Losartan—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.23e-05	0.000614	CbGpPWpGaD
Losartan—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.22e-05	0.000614	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—NDUFA12—bone cancer	6.19e-05	0.000611	CbGpPWpGaD
Losartan—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.14e-05	0.000606	CbGpPWpGaD
Losartan—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.14e-05	0.000605	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.99e-05	0.000591	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.97e-05	0.000589	CbGpPWpGaD
Losartan—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.89e-05	0.000581	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	5.61e-05	0.000554	CbGpPWpGaD
Losartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	5.61e-05	0.000554	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—NDUFA12—bone cancer	5.36e-05	0.000529	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—ENO2—bone cancer	5.35e-05	0.000528	CbGpPWpGaD
Losartan—ALB—Metabolism—NDUFA12—bone cancer	5.33e-05	0.000526	CbGpPWpGaD
Losartan—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.32e-05	0.000525	CbGpPWpGaD
Losartan—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.25e-05	0.000518	CbGpPWpGaD
Losartan—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.16e-05	0.000509	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—NT5C3A—bone cancer	5.13e-05	0.000506	CbGpPWpGaD
Losartan—ALB—Folate Metabolism—TP53—bone cancer	5.05e-05	0.000498	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—ENO2—bone cancer	5.04e-05	0.000497	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—DHFR—bone cancer	4.96e-05	0.000489	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NDUFA12—bone cancer	4.79e-05	0.000472	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—DHFR—bone cancer	4.68e-05	0.000461	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NDUFA12—bone cancer	4.67e-05	0.000461	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—GNA11—bone cancer	4.64e-05	0.000457	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—SMO—bone cancer	4.58e-05	0.000452	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—ENO2—bone cancer	4.55e-05	0.000449	CbGpPWpGaD
Losartan—ALB—Hemostasis—SPARC—bone cancer	4.52e-05	0.000446	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.44e-05	0.000438	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—NT5C3A—bone cancer	4.44e-05	0.000438	CbGpPWpGaD
Losartan—ALB—Metabolism—NT5C3A—bone cancer	4.42e-05	0.000436	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—GNA11—bone cancer	4.37e-05	0.000431	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NDUFA12—bone cancer	4.36e-05	0.00043	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—DHFR—bone cancer	4.22e-05	0.000416	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—CYP3A4—bone cancer	4.2e-05	0.000415	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—GNA11—bone cancer	4.19e-05	0.000413	CbGpPWpGaD
Losartan—ALB—Hemostasis—GNA11—bone cancer	4.14e-05	0.000408	CbGpPWpGaD
Losartan—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.11e-05	0.000405	CbGpPWpGaD
Losartan—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.05e-05	0.000399	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—NT5C3A—bone cancer	3.97e-05	0.000391	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—CYP3A4—bone cancer	3.96e-05	0.000391	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—GNA11—bone cancer	3.94e-05	0.000389	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.94e-05	0.000389	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—ATF1—bone cancer	3.89e-05	0.000384	CbGpPWpGaD
Losartan—ABCB1—Metabolism—NT5C3A—bone cancer	3.87e-05	0.000382	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IL3—bone cancer	3.8e-05	0.000375	CbGpPWpGaD
Losartan—ALB—Hemostasis—IL3—bone cancer	3.75e-05	0.00037	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NDUFA12—bone cancer	3.73e-05	0.000368	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—ENO2—bone cancer	3.7e-05	0.000365	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—NT5C3A—bone cancer	3.62e-05	0.000357	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—GSTP1—bone cancer	3.6e-05	0.000355	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—CYP3A4—bone cancer	3.58e-05	0.000353	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—DHFR—bone cancer	3.43e-05	0.000338	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—GSTP1—bone cancer	3.39e-05	0.000334	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—ENO2—bone cancer	3.39e-05	0.000334	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.29e-05	0.000325	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	3.25e-05	0.00032	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—GNA11—bone cancer	3.2e-05	0.000316	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.18e-05	0.000313	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—DHFR—bone cancer	3.14e-05	0.00031	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—NT5C3A—bone cancer	3.09e-05	0.000305	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—GSTP1—bone cancer	3.06e-05	0.000302	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	3.06e-05	0.000301	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GNA11—bone cancer	2.94e-05	0.00029	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—CYP3A4—bone cancer	2.91e-05	0.000287	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NDUFA12—bone cancer	2.88e-05	0.000284	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.86e-05	0.000282	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.66e-05	0.000263	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.65e-05	0.000261	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—GSTP1—bone cancer	2.48e-05	0.000245	CbGpPWpGaD
Losartan—ALB—Hemostasis—PLAU—bone cancer	2.46e-05	0.000243	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—NT5C3A—bone cancer	2.38e-05	0.000235	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—GSTP1—bone cancer	2.28e-05	0.000225	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.25e-05	0.000222	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—ENO2—bone cancer	2.25e-05	0.000222	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—KIT—bone cancer	2.22e-05	0.000219	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—DHFR—bone cancer	2.08e-05	0.000206	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—BRAF—bone cancer	2.08e-05	0.000205	CbGpPWpGaD
Losartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	2.02e-05	0.000199	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GNA11—bone cancer	1.95e-05	0.000192	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—ENO2—bone cancer	1.95e-05	0.000192	CbGpPWpGaD
Losartan—ALB—Metabolism—ENO2—bone cancer	1.94e-05	0.000191	CbGpPWpGaD
Losartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.89e-05	0.000186	CbGpPWpGaD
Losartan—UGT1A3—Metabolism—PTGS2—bone cancer	1.86e-05	0.000184	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—DHFR—bone cancer	1.81e-05	0.000178	CbGpPWpGaD
Losartan—ALB—Metabolism—DHFR—bone cancer	1.8e-05	0.000177	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—CYP3A4—bone cancer	1.77e-05	0.000174	CbGpPWpGaD
Losartan—SLCO1B3—Metabolism—PTGS2—bone cancer	1.76e-05	0.000173	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—MDM2—bone cancer	1.75e-05	0.000172	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—ENO2—bone cancer	1.74e-05	0.000171	CbGpPWpGaD
Losartan—ABCB1—Metabolism—ENO2—bone cancer	1.7e-05	0.000167	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GNA11—bone cancer	1.69e-05	0.000166	CbGpPWpGaD
Losartan—ALB—Metabolism—GNA11—bone cancer	1.68e-05	0.000165	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—DHFR—bone cancer	1.61e-05	0.000159	CbGpPWpGaD
Losartan—UGT2B7—Metabolism—PTGS2—bone cancer	1.58e-05	0.000156	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—ENO2—bone cancer	1.58e-05	0.000156	CbGpPWpGaD
Losartan—ABCB1—Metabolism—DHFR—bone cancer	1.57e-05	0.000155	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—CYP3A4—bone cancer	1.53e-05	0.000151	CbGpPWpGaD
Losartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.52e-05	0.00015	CbGpPWpGaD
Losartan—ALB—Metabolism—CYP3A4—bone cancer	1.52e-05	0.00015	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—JUN—bone cancer	1.52e-05	0.00015	CbGpPWpGaD
Losartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.51e-05	0.000149	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—GSTP1—bone cancer	1.51e-05	0.000149	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GNA11—bone cancer	1.51e-05	0.000149	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—MMP9—bone cancer	1.48e-05	0.000146	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GNA11—bone cancer	1.47e-05	0.000145	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—DHFR—bone cancer	1.47e-05	0.000145	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GNA11—bone cancer	1.37e-05	0.000135	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—CYP3A4—bone cancer	1.37e-05	0.000135	CbGpPWpGaD
Losartan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.36e-05	0.000134	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—ENO2—bone cancer	1.35e-05	0.000134	CbGpPWpGaD
Losartan—ABCB1—Metabolism—CYP3A4—bone cancer	1.33e-05	0.000131	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—GSTP1—bone cancer	1.31e-05	0.000129	CbGpPWpGaD
Losartan—ALB—Metabolism—GSTP1—bone cancer	1.3e-05	0.000128	CbGpPWpGaD
Losartan—UGT1A1—Metabolism—PTGS2—bone cancer	1.29e-05	0.000127	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—DHFR—bone cancer	1.26e-05	0.000124	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000123	CbGpPWpGaD
Losartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.24e-05	0.000122	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—EGFR—bone cancer	1.19e-05	0.000118	CbGpPWpGaD
Losartan—SLCO1B1—Metabolism—PTGS2—bone cancer	1.18e-05	0.000116	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GNA11—bone cancer	1.17e-05	0.000116	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—GSTP1—bone cancer	1.17e-05	0.000115	CbGpPWpGaD
Losartan—ABCB1—Metabolism—GSTP1—bone cancer	1.14e-05	0.000112	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—GSTP1—bone cancer	1.06e-05	0.000105	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—CYP3A4—bone cancer	1.06e-05	0.000105	CbGpPWpGaD
Losartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.06e-05	0.000104	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—ENO2—bone cancer	1.04e-05	0.000103	CbGpPWpGaD
Losartan—AGTR1—Signaling Pathways—TP53—bone cancer	1e-05	9.88e-05	CbGpPWpGaD
Losartan—ALB—Hemostasis—TP53—bone cancer	9.89e-06	9.76e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—DHFR—bone cancer	9.69e-06	9.56e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—GSTP1—bone cancer	9.1e-06	8.98e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GNA11—bone cancer	9.06e-06	8.93e-05	CbGpPWpGaD
Losartan—CYP3A5—Metabolism—PTGS2—bone cancer	7.83e-06	7.72e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—GSTP1—bone cancer	7.02e-06	6.93e-05	CbGpPWpGaD
Losartan—CYP2C8—Metabolism—PTGS2—bone cancer	6.78e-06	6.69e-05	CbGpPWpGaD
Losartan—ALB—Metabolism—PTGS2—bone cancer	6.74e-06	6.65e-05	CbGpPWpGaD
Losartan—CYP2C19—Metabolism—PTGS2—bone cancer	6.05e-06	5.97e-05	CbGpPWpGaD
Losartan—ABCB1—Metabolism—PTGS2—bone cancer	5.91e-06	5.82e-05	CbGpPWpGaD
Losartan—CYP2C9—Metabolism—PTGS2—bone cancer	5.52e-06	5.44e-05	CbGpPWpGaD
Losartan—CYP1A2—Metabolism—PTGS2—bone cancer	4.71e-06	4.65e-05	CbGpPWpGaD
Losartan—CYP3A4—Metabolism—PTGS2—bone cancer	3.64e-06	3.59e-05	CbGpPWpGaD
